AR039628A2 - Formulacion masticable de carprofeno, implante y composicion terapeutica - Google Patents
Formulacion masticable de carprofeno, implante y composicion terapeuticaInfo
- Publication number
- AR039628A2 AR039628A2 ARP030101251A ARP030101251A AR039628A2 AR 039628 A2 AR039628 A2 AR 039628A2 AR P030101251 A ARP030101251 A AR P030101251A AR P030101251 A ARP030101251 A AR P030101251A AR 039628 A2 AR039628 A2 AR 039628A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- implant
- formulation
- carprophene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación masticable, un implante y una composición que comprenden carprofeno. Una composición caracterizada porque comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (1), en la que, R2 es -(CXY)n-C(O)-A, donde A es hidroxi, alcoxi (C1-4), amino, hidroxiamino, mono-alquilamino(C1-2), di-alquilamino(C1-2); X e Y son, independientemente, H o alquilo(C1-2); y n es 1 ó 2; R6 es halógeno, alquilo (C1-3), trifluorometilo o nitro; R9 es H; alquilo(C1-2); fenilo o fenil-alquilo(C1-2), donde el fenilo está opcionalmente mono-sustituido con fluoro o cloro; -C(=O)-R, donde R es alquilo(C1-2) o fenilo, opcionalmente mono-sustituido con fluoro o cloro; o -C(=O)-O-R1, donde R1 es alquilo(C1-2); donde X e Y son diferentes, los enantiómeros (-)(R) y (+)(S) de los mismos; y todas las formas de sales farmacéuticamente aceptables, profármacos y metabolitos de los mismos, en una forma de dosificación controlada que sea capaz de mantener los niveles de plasma por sobre aproximadamente 10 micro g/ml durante un período mayor a 10,5 horas. Estos son útiles en el tratamiento del dolor y de la inflamación con una menor incidencia de efectos secundarios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039628A2 true AR039628A2 (es) | 2005-03-02 |
Family
ID=21939053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (es) | 1997-05-05 | 1998-05-05 | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento |
| ARP030101251A AR039628A2 (es) | 1997-05-05 | 2003-04-09 | Formulacion masticable de carprofeno, implante y composicion terapeutica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (es) | 1997-05-05 | 1998-05-05 | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (es) |
| JP (1) | JP2000513020A (es) |
| KR (2) | KR20010012300A (es) |
| CN (1) | CN1255059A (es) |
| AP (1) | AP9801234A0 (es) |
| AR (2) | AR011726A1 (es) |
| AU (1) | AU6932198A (es) |
| BG (1) | BG103852A (es) |
| BR (1) | BR9808720A (es) |
| CA (1) | CA2288759A1 (es) |
| DZ (1) | DZ2479A1 (es) |
| EA (1) | EA003696B1 (es) |
| GT (1) | GT199800063A (es) |
| HR (1) | HRP980244A2 (es) |
| HU (1) | HUP0001286A3 (es) |
| ID (1) | ID21311A (es) |
| IL (1) | IL132570A0 (es) |
| IS (1) | IS5220A (es) |
| MA (1) | MA26491A1 (es) |
| NO (1) | NO995389L (es) |
| NZ (1) | NZ500183A (es) |
| OA (1) | OA11213A (es) |
| PA (1) | PA8450601A1 (es) |
| PE (1) | PE72599A1 (es) |
| PL (1) | PL337003A1 (es) |
| SK (1) | SK148199A3 (es) |
| TN (1) | TNSN98059A1 (es) |
| TW (1) | TW590773B (es) |
| UY (1) | UY24989A1 (es) |
| WO (1) | WO1998050033A1 (es) |
| YU (1) | YU55899A (es) |
| ZA (1) | ZA983722B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| US6506785B2 (en) * | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| EP1123091A1 (en) * | 1998-10-23 | 2001-08-16 | Merck Frosst Canada & Co. | Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| EP1637137A3 (en) * | 1999-03-10 | 2006-07-05 | G.D. Searle LLC | Method and composition for administering a cyclooxygenase-2 inhibitor to animals |
| WO2001034204A1 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| JP2004521856A (ja) * | 2000-05-15 | 2004-07-22 | メルク フロスト カナダ アンド カンパニー | Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物 |
| CA2411960C (en) | 2000-06-13 | 2010-10-12 | Wyeth | Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| EP1307538B1 (en) | 2000-08-07 | 2009-01-07 | Vanderbilt University | Detection of cox-2 activity and anandamide metabolites |
| WO2003007875A2 (en) * | 2001-07-16 | 2003-01-30 | Hoegestaett Edward | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| DK1534305T3 (da) | 2003-05-07 | 2007-02-05 | Osteologix As | Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte |
| CA2533101A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| US20080269310A1 (en) * | 2005-05-20 | 2008-10-30 | Adrian Paul Foster | Synergistic Combinations |
| DK2079456T3 (da) | 2007-04-04 | 2013-03-18 | Sigmoid Pharma Ltd | Farmaceutiske cyclosporinsammensætninger |
| EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| BRPI1012196B1 (pt) | 2009-05-18 | 2021-11-30 | Sublimity Therapeutics Limited | Composição compreendendo gotas de óleo |
| EP2464341B1 (en) | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| ES2907285T3 (es) | 2014-03-06 | 2022-04-22 | Elanco Animal Health Incorporated | Composiciones de grapiprant y procedimientos de uso de las mismas |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR20170102223A (ko) | 2014-11-07 | 2017-09-08 | 시그모이드 파마 리미티드 | 사이클로스포린을 포함하는 조성물 |
| CA2972996A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/xx active
- 1998-04-30 TW TW087106689A patent/TW590773B/zh not_active IP Right Cessation
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/ko not_active Application Discontinuation
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/pt not_active IP Right Cessation
- 1998-05-01 EA EA199900895A patent/EA003696B1/ru not_active IP Right Cessation
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/hu unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/ko not_active Application Discontinuation
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 IL IL13257098A patent/IL132570A0/xx unknown
- 1998-05-01 PL PL98337003A patent/PL337003A1/xx unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/ja active Pending
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Application Discontinuation
- 1998-05-01 CN CN98804845A patent/CN1255059A/zh active Pending
- 1998-05-01 SK SK1481-99A patent/SK148199A3/sk unknown
- 1998-05-01 ID IDP980651A patent/ID21311A/id unknown
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-01 YU YU55899A patent/YU55899A/sh unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/xx unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/fr unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/es not_active Application Discontinuation
- 1998-05-04 PE PE1998000335A patent/PE72599A1/es not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 MA MA25059A patent/MA26491A1/fr unknown
- 1998-05-04 GT GT199800063A patent/GT199800063A/es unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/hr not_active Application Discontinuation
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/es unknown
- 1998-05-05 AR ARP980102089A patent/AR011726A1/es unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/is unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/xx unknown
- 1999-11-04 NO NO995389A patent/NO995389L/no not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039628A2 (es) | Formulacion masticable de carprofeno, implante y composicion terapeutica | |
| AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
| DK0524587T3 (da) | Terapeutiske sammensætninger til intranasal indgivelse indeholdende Ketorolac R | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| RU97117350A (ru) | Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы | |
| PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
| MY106552A (en) | Novel pyrido[2,3-f] [1,4]thiazepines and pyrido[3,2-b] [1,5] benzothiazepines. | |
| DE60003194D1 (de) | Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren | |
| SE0104333D0 (sv) | Therapeutic agents | |
| NO964216L (no) | Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter | |
| CO5271694A1 (es) | Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion | |
| SE9900190D0 (sv) | New compounds | |
| PE20050139A1 (es) | Compuestos derivados de acidos hidroxamicos y composiciones farmaceuticas | |
| AR013538A1 (es) | Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos | |
| NO171363C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive oksysalicylaminoderivater | |
| IT1244696B (it) | Derivato chinolonico ad attivita' antibatterica e mucolitica | |
| ES8104271A1 (es) | Procedimiento para la preparacion de 5-(2-((3-(1,3-benzodio-sol-5-il)-1-metilpropil)amino)-1-hidroxietil-2-metoxibenza- mida y de sus sales e isomeros opticos farmaceuticamente aceptables |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |